Eton Pharmaceuticals
Eton Pharmaceuticals' revenue rose 104.9% to $80 million in fiscal 2025. Its operating margin was −1.1%, up from −6.7% a year earlier. Free cash flow was $10 million, up 980.7%. The diluted share count rose 3.9%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Eton Pharmaceuticals does
Eton Pharmaceuticals develops and sells treatments for rare diseases. It has eight products on the market, including INCRELEX, ALKINDI SPRINKLE, KHINDIVI, GALZIN and PKU GOLIKE, and five more candidates in late-stage development.
It earns revenue from selling these products, mostly in the United States. INCRELEX treats children with severe primary insulin-like growth factor 1 deficiency, and Eton bought and launched it in December 2024. ALKINDI SPRINKLE and KHINDIVI are hydrocortisone products for children with adrenocortical insufficiency, a shortage of hormones from the adrenal glands. GALZIN is a maintenance treatment for Wilson disease, in which the body holds too much copper. It sells ALKINDI SPRINKLE with a sales force aimed at pediatric endocrinologists.
Eton says it competes with other biotechnology and pharmaceutical companies.
Its biggest risks, as it describes them
- US drug pricing and Medicare rules may cut the prices it gets and demand for its products.
- Government price reporting and discount programs add complex duties that can lower its net prices.
- Insurer coverage and cost controls may limit what it can charge.
- It depends on its approved products and new candidates for revenue.
- Its focus on rare diseases means small patient groups.
Income statement
Eton Pharmaceuticals lost money in fiscal 2025: a net loss of $5 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 14 | 16 | 21 | 15 | 26 |
| Debt incl. finance leases | 5 | 5 | 0 | 30 | 31 |
| Net debt (negative means net cash) | −9 | −11 | −21 | 15 | 5 |
| Net debt to EBITDA | — | — | — | — | 1.4x |
| Debt to equity | 0.3x | 0.4x | 0.0x | 1.2x | 1.2x |
| Interest coverage | −1.4x | −8.7x | −1.1x | −1.3x | −0.2x |
| Current ratio | 5.2x | 3.1x | 1.6x | 2.1x | 1.6x |
| Quick ratio | 5.1x | 3.0x | 1.6x | 1.3x | 1.2x |
Cash flow
Projections
Project Eton Pharmaceuticals' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What Eton Pharmaceuticals says to expect
- Full year 2026: revenue and Adjusted EBITDA margin
The Company now expects 2026 revenue of more than $175 million, an increase from its previous guidance of more than $145 million. The Company also expects at least a 40% Adjusted EBITDA margin for 2026, up from its previous guidance of at least 35%.
Insider trades
Over the 12 months between November 14, 2025 and November 13, 2026, no insider bought Eton Pharmaceuticals shares on the open market, and 5 insiders sold $25.2 million.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 28, 2026 | Paul Maier VDirector | Sold | 50,000 | $59.07 | $3.0 million | Form 4 |
| Aug 24, 2026 | David KrempaChief Business Officer | Sold | 25,000 | $65.07 | $1.6 million | Form 4 |
| Aug 20, 2026 | Sean BrynjelsenPresident & CEO, Director | Sold | 91,022 | $60.70 | $5.5 million | Form 4 |
| Aug 19, 2026 | Sean BrynjelsenPresident & CEO, Director | Sold | 8,978 | $62.65 | $562,472 | Form 4 |
| Jul 14, 2026 | Opaleye Management Inc.10% owner | Sold | 28,315 | $37.54 | $1.1 million | Form 4 |
| Jul 7, 2026 | Opaleye Management Inc.10% owner | Sold | 26,685 | $38.37 | $1.0 million | Form 4 |
| Jul 6, 2026 | Opaleye Management Inc.10% owner | Sold | 10,000 | $38.00 | $380,000 | Form 4 |
| Jul 2, 2026 | Opaleye Management Inc.10% owner | Sold | 90,000 | $37.39 | $3.4 million | Form 4 |
| Jun 17, 2026 | Jennifer McKie AdamsDirector | Sold | 50,000 | $32.48 | $1.6 million | Form 4 |
| May 28, 2026 | Sean BrynjelsenPresident & CEO, Director | Sold | 120,000 | $31.88 | $3.8 million | Form 4 |
| May 27, 2026 | David KrempaChief Business Officer | Sold | 19,679 | $31.47 | $619,298 | Form 4 |
| May 26, 2026 | David KrempaChief Business Officer | Sold | 37,524 | $31.49 | $1.2 million | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 5 of 9 | 3 of 9 | 4 of 9 |
| Rule of 40 | 70.4% | 25.7% | 117.7% |
| Altman Z'' | −7.75 | −2.54 | −2.05 |
| Accruals ratio | −27.3% | −8.9% | −18.0% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Pass | Pass | Pass |
| Return on assets rose | Pass | Fail | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Pass | Fail | Pass |
| Current ratio rose | Fail | Pass | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Fail | Fail | Fail |
| Revenue rose relative to assets | Pass | Fail | Fail |
| F-score | 5 of 9 | 3 of 9 | 4 of 9 |
Compare
Put Eton Pharmaceuticals side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Eton Pharmaceuticals | FY25 | 104.9% | −1.1% | 12.8% | −1.9% | 1.4x | 4 | |
| Nurix Therapeutics | FY25 | 54.0% | −340.2% | −313.7% | — | — | — | Compare |
| Viridian Therapeutics | FY25 | 23,359.9% | −512.9% | −390.8% | — | — | — | Compare |
| Kura Oncology | FY25 | 25.2% | −449.9% | −104.8% | — | — | 3 | Compare |
| Nuvation Bio | FY25 | 699.0% | −338.7% | −288.4% | — | — | — | Compare |
8 years of figures
| Fiscal year | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | 1 | 0 | 22 | 21 | 32 | 39 | 80 |
| Revenue growth | — | — | −95.9% | 55,879.5% | −2.7% | 48.9% | 23.3% | 104.9% |
| Gross profit | — | 0 | −0 | 19 | 14 | 21 | 23 | 43 |
| Research and development | 6 | 12 | 14 | 6 | 4 | 3 | 3 | 8 |
| Operating income | −10 | −19 | −27 | −2 | −8 | −1 | −3 | −1 |
| Net income | −13 | −18 | −28 | −2 | −9 | −1 | −4 | −5 |
| Diluted EPS (US$) | −5.80 | −1.03 | −1.33 | −0.08 | — | — | — | — |
| Diluted shares (millions) | 6 | 18 | 21 | 25 | 25 | 26 | 26 | 27 |
| Cash flow | ||||||||
| Cash from operations | −8 | −18 | −22 | −5 | 5 | 7 | 1 | 10 |
| Capital expenditure | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free cash flow | −8 | −19 | −22 | −5 | 5 | 7 | 1 | 10 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 30 | 0 |
| Stock-based compensation | 2 | 2 | 3 | 3 | 4 | 3 | 3 | 6 |
| Balance sheet at fiscal year end | ||||||||
| Cash and short-term investments | 27 | 12 | 21 | 14 | 16 | 21 | 15 | 26 |
| Debt incl. finance leases | — | 4 | 6 | 5 | 5 | 0 | 30 | 31 |
| Total assets | 28 | 17 | 26 | 28 | 25 | 32 | 76 | 92 |
| Total liabilities | 2 | 6 | 11 | 10 | 12 | 16 | 52 | 66 |
| Shareholders' equity | 26 | 10 | 18 | 18 | 13 | 16 | 24 | 26 |
| Margins and ratios | ||||||||
| Gross margin | — | 52.8% | −1,018.0% | 87.0% | 67.4% | 66.6% | 60.0% | 53.5% |
| Operating margin | — | −1,939.6% | −69,515.4% | −6.8% | −38.9% | −3.8% | −6.7% | −1.1% |
| Net margin | — | −1,910.3% | −71,717.9% | −8.9% | −42.5% | −3.0% | −9.8% | −5.8% |
| Free cash flow margin | — | −1,994.0% | −57,425.6% | −21.7% | 22.5% | 21.5% | 2.4% | 12.8% |
| Rule of 40 (growth + FCF margin) | — | — | −57,521.6% | 55,857.8% | 19.9% | 70.4% | 25.7% | 117.7% |
| Return on capital | — | — | −727.1% | −20.8% | −122.6% | — | −12.3% | −1.9% |
| Return on equity | — | −99.4% | −198.5% | −11.1% | −58.8% | −6.6% | −19.2% | −18.2% |
| Return on assets | — | −80.7% | −128.9% | −7.3% | −34.4% | −3.3% | −7.1% | −5.5% |
| Net debt to EBITDA | — | — | — | — | — | — | — | 1.4x |